GLP-1 Weight Loss: What Trial Data Actually Shows

GLP-1 receptor agonists — semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) — are the most effective pharmacological weight-loss options approved to date. But trial averages and real-world results often diverge. Use our GLP-1 weight loss projector to model a range based on published trial data, then read on to understand what those numbers mean.

What GLP-1 Agonists Are

GLP-1 (glucagon-like peptide-1) is a hormone your gut releases after meals. It slows gastric emptying, stimulates insulin release, reduces glucagon, and signals satiety to the brain. GLP-1 receptor agonists are synthetic molecules that mimic these signals for much longer than endogenous GLP-1. Tirzepatide additionally activates the GIP receptor, which appears to enhance weight-loss efficacy.

What STEP 1 Showed (Semaglutide)

The STEP 1 trial (Wilding et al., NEJM 2021) randomized 1,961 adults with overweight or obesity to weekly semaglutide 2.4 mg or placebo, alongside lifestyle counseling. Over 68 weeks:

• Mean weight change: -14.9% on semaglutide vs. -2.4% on placebo
• ≥5% weight loss: 86% of semaglutide group vs. 32% of placebo
• ≥15% weight loss: 50% of semaglutide group vs. 5% of placebo
• Discontinuation for adverse events: about 7% on drug vs. 3% on placebo

What SURMOUNT-1 Showed (Tirzepatide)

SURMOUNT-1 (Jastreboff et al., NEJM 2022) randomized 2,539 adults to weekly tirzepatide (5, 10, or 15 mg) or placebo over 72 weeks. Mean weight change:

• Tirzepatide 5 mg: -15.0%
• Tirzepatide 10 mg: -19.5%
• Tirzepatide 15 mg: -20.9%
• Placebo: -3.1%

At 15 mg, about 57% of participants achieved ≥20% weight loss — a result that had not previously been seen outside bariatric surgery.

Why Your Results May Differ

Trial averages are averages. Individual response varies for several reasons:

• Adherence and tolerability. Side effects (nausea, GI issues) lead some patients to stay on lower doses or discontinue
• Starting BMI and body composition. People with higher starting weights often lose more absolute weight but similar percentages
• Diet and activity behavior. Trial protocols included lifestyle counseling; real-world patients may not get the same support
• Genetics and metabolic context. Some patients are high responders, others low — no clear predictor exists yet
• Concurrent medications. Drugs that increase appetite (some antipsychotics, steroids, certain antidepressants) may blunt response

Weight Regain After Stopping

The STEP 4 extension trial showed that participants who stopped semaglutide regained about two-thirds of their lost weight within a year. This is consistent with obesity being a chronic condition requiring chronic management — similar to blood pressure or cholesterol treatment. Long-term use is the clinical expectation, not a short course.

Cardiovascular and Metabolic Benefits

Beyond weight, trials have shown:

• Meaningful reductions in HbA1c, blood pressure, and triglycerides
• The SELECT trial (semaglutide 2.4 mg in adults with overweight and existing CV disease) showed about a 20% reduction in major adverse cardiovascular events
• Improvements in NAFLD markers, sleep apnea severity, and kidney function in some sub-analyses

These benefits may be partially independent of weight loss, though the mechanisms remain active research areas.

Common Side Effects

Per FDA prescribing information, the most common adverse events are gastrointestinal:

• Nausea (most common, typically decreasing over weeks)
• Vomiting, diarrhea, constipation
• Fatigue, headache
• Injection site reactions

Less common but important concerns include pancreatitis, gallbladder disease, and thyroid C-cell tumor risk noted in rodent studies (medullary thyroid carcinoma and MEN 2 are contraindications on current labels).

Muscle Loss and Nutrition

Rapid weight loss on GLP-1s is not exclusively fat — some lean mass is lost, similar to other significant weight-loss methods. Clinicians increasingly emphasize:

• Adequate protein intake (often 1.2-1.6 g/kg body weight)
• Resistance training to protect muscle
• Preventing nutrient deficiencies when appetite drops sharply

Who Is Eligible Under FDA Labeling

For adults, current FDA-approved labeling for chronic weight management requires:

• BMI ≥30, or
• BMI ≥27 with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, etc.)

Insurance coverage often imposes additional requirements. See our dedicated post on GLP-1 eligibility for more detail.

Next Steps

Use our GLP-1 weight loss projector to model a realistic range based on your starting weight, dose, and timeline — always understanding that individual response varies. These medications work best alongside nutrition, protein-preserving habits, and movement, managed by a licensed prescriber who can monitor progress and side effects.